Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr).

Rajamani S, Anderson CL, Valdivia CR, Eckhardt LL, Foell JD, Robertson GA, Kamp TJ, Makielski JC, Anson BD, January CT.

Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1278-88. Epub 2005 Oct 14.

2.

Deciphering hERG channels: molecular basis of the rapid component of the delayed rectifier potassium current.

Jonsson MK, van der Heyden MA, van Veen TA.

J Mol Cell Cardiol. 2012 Sep;53(3):369-74. doi: 10.1016/j.yjmcc.2012.06.011. Epub 2012 Jun 26. Review.

PMID:
22742967
3.

ERG proteins and functional cardiac I(Kr) channels in rat, mouse, and human heart.

Pond AL, Nerbonne JM.

Trends Cardiovasc Med. 2001 Oct;11(7):286-94. Review.

PMID:
11709283
4.

Pharmacology of cardiac potassium channels.

Li GR, Dong MQ.

Adv Pharmacol. 2010;59:93-134. doi: 10.1016/S1054-3589(10)59004-5. Review.

PMID:
20933200
5.

[HERG K+ channel, the target of anti-arrhythmias drugs].

Guan FY, Yang SJ.

Yao Xue Xue Bao. 2007 Jul;42(7):687-91. Review. Chinese.

PMID:
17882949
6.

HERG1 channelopathies.

Sanguinetti MC.

Pflugers Arch. 2010 Jul;460(2):265-76. doi: 10.1007/s00424-009-0758-8. Epub 2009 Nov 22. Review.

7.

Theoretical possibilities for the development of novel antiarrhythmic drugs.

Varró A, Biliczki P, Iost N, Virág L, Hála O, Kovács P, Mátyus P, Papp JG.

Curr Med Chem. 2004 Jan;11(1):1-11. Review.

PMID:
14754422
8.

Structural determinants and biophysical properties of HERG and KCNQ1 channel gating.

Tristani-Firouzi M, Sanguinetti MC.

J Mol Cell Cardiol. 2003 Jan;35(1):27-35. Review.

PMID:
12623297
9.

Pharmacology of cardiac potassium channels.

Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E.

Cardiovasc Res. 2004 Apr 1;62(1):9-33. Review.

PMID:
15023549
10.

I(Kr): the hERG channel.

Tseng GN.

J Mol Cell Cardiol. 2001 May;33(5):835-49. Review.

PMID:
11343409
11.
12.

Role of ERG1 isoforms in modulation of ERG1 channel trafficking and function.

Larsen AP.

Pflugers Arch. 2010 Oct;460(5):803-12. doi: 10.1007/s00424-010-0855-8. Epub 2010 Jun 24. Review.

PMID:
20574821
13.

KCNH2 pharmacogenomics summary.

Oshiro C, Thorn CF, Roden DM, Klein TE, Altman RB.

Pharmacogenet Genomics. 2010 Dec;20(12):775-7. doi: 10.1097/FPC.0b013e3283349e9c. Review. No abstract available.

14.

hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers.

Lastraioli E, Lottini T, Bencini L, Bernini M, Arcangeli A.

Biomed Res Int. 2015;2015:896432. doi: 10.1155/2015/896432. Epub 2015 Aug 3. Review.

15.

hERG1 potassium channel in cancer cells: a tool to reprogram immortality.

Gentile S.

Eur Biophys J. 2016 Oct;45(7):649-655. Epub 2016 Sep 20. Review.

PMID:
27649700
16.

New Trends in Cancer Therapy: Targeting Ion Channels and Transporters.

Arcangeli A, Becchetti A.

Pharmaceuticals (Basel). 2010 Apr 20;3(4):1202-1224. Review.

Supplemental Content

Support Center